[
  {
    "product_code": "BI 1015550",
    "product_name": "Nerandomilast",
    "modality_name": "Small Molecule", 
    "product_type": "NME",
    "therapeutic_area": "Respiratory",
    "mechanism_of_action": "Preferential PDE4B inhibitor",
    "current_phase": "Registration",
    "lead_indication": "IPF",
    "expected_launch_year": 2025,
    
    "primary_packaging": "Blister",
    "route_of_administration": "Oral",
    "granulation_technology": "Twin Screw",
    "ppq_status": "Completed",
    "timeline_variance_days": -10,
    "timeline_variance_baseline": "AD 2024",
    "development_program_name": "FIBRONEERâ„¢",
    
    "ds_suppliers": [
      {"name": "ING", "site": "Ingelheim", "role": "Primary", "status": "active"}
    ],
    "dp_suppliers": [
      {"name": "ING_SoL", "site": "Launch Site", "role": "Launch", "status": "ready"},
      {"name": "Koropi", "site": "Greece", "role": "Commercial", "status": "planned"}
    ],
    
    "operational_risks": [
      {
        "risk": "TiO2 formulation bridging requires in-vivo BE study",
        "severity": "major", 
        "mitigation": "Dual-path development strategy",
        "status": "managed"
      }
    ],
    
    "clinical_trials": [
      {"program": "FIBRONEER", "geography": "40+ countries", "phase": "Phase III"}
    ]
  }
]